Increased Oversight of Drug Precursors

Summary#

This is a proposed set of changes to the Precursor Control Regulations to give regulators more tools to stop the illegal production of fentanyl and other synthetic drugs in Canada. If adopted, the proposal would add new reporting and personnel rules for businesses that handle precursor chemicals, tighten how certain over‑the‑counter products with ephedrine/pseudoephedrine are sold, and expand import controls on parts for pill presses and encapsulators.

What it does#

• Requires licensed and registered dealers working with precursors to file a written report with Health Canada within 72 hours when they have reasonable grounds to suspect a transaction may be linked to diversion to an illicit market. Reports must be kept for two years.
• Protects dealers who report in good faith from civil suits and gives partial protection against self‑incrimination for reporting suspicious transactions or loss/theft.
• Requires dealers to take “reasonable steps” to reduce the risk that employees will help divert precursors. That includes considering whether staff with access have, in the past 10 years, adult convictions for certain drug or criminal offences.
• Moves condition‑of‑sale rules for products containing ephedrine and/or pseudoephedrine into the Precursor Control Regulations and extends them to some non‑prescription drugs (NPDs):
  • Non‑combination natural health products with ephedrine/pseudoephedrine would only be sold in a pharmacy setting (behind the counter).
  • Combination products could be available for self‑selection in pharmacies, but a pharmacist must be available on request to discuss the purchase.
  • These rules apply to both physical and online pharmacy sales.
• Gives the Minister of Health more flexibility to manage licences and registrations:
  • The Minister could add, change, or remove licence/registration conditions at any time (with prior notice in most cases).
  • The Minister could partially suspend specific activities on a licence or registration without prior notice in urgent situations.
  • The Minister could add conditions to transit and transhipment permits when issued.
• Expands import‑registration controls under Schedule IX to the Controlled Drugs and Substances Act to cover certain component parts (punches, moulds and dies) used in pill presses or encapsulators. Importers would have to register these parts before import and show proof at the border.
• Repeals the Order Establishing Supplementary Rules Respecting the Sale of Natural Health Products Containing Ephedrine or Pseudoephedrine and carries those retail sale rules into the PCR to avoid duplication.

Who's affected#

• Licensed and registered dealers that handle precursors (Health Canada estimates 429 licensed/registered sites and 355 companies).
• Pharmacists, health‑care practitioners and hospitals (they remain the permitted retail sellers of these ephedrine/pseudoephedrine products).
• Importers of component parts for pill presses/encapsulators (Health Canada estimates about 1,200 component parts imported annually).
• Small businesses: most impacted firms are small — the analysis says about 386 small businesses would be affected.
• Health Canada, the Canada Border Services Agency (CBSA), and law enforcement agencies (they would use the new reports and registration information).
• Consumers who buy over‑the‑counter decongestants or natural health products containing ephedrine/pseudoephedrine (some purchases would require pharmacist interaction or be kept behind the counter).
• Note: these are proposed changes. They are not law yet and would come into force if and when the regulations are finalized and published in the Canada Gazette, Part II.

Costs reported by the government’s analysis:

• Total estimated costs: about $2.04 million in present value over 10 years (PV $2,037,490), with an annualized value of $290,093.
• Administrative burden (monetized): PV about $83,722 (annualized $11,920).
• Small business impacts: PV about $1.50 million and an average PV cost per small business of $3,890 (annualized $554).

Why it matters#

• The government says these changes are meant to slow the rise of domestic illegal fentanyl manufacture by making it harder to get precursor chemicals and the equipment that helps produce pills. That could reduce overdoses linked to illicit fentanyl over time.
• For businesses, the changes mean more paperwork, new employee‑screening steps, and some limits on who can buy certain products. That will bring compliance costs, especially for small companies and importers of device parts.
• For shoppers, some common non‑prescription products that contain ephedrine or pseudoephedrine may become less visible on shelves and might require a quick talk with a pharmacist before purchase. Access for legitimate medical uses is intended to be preserved.
• The proposal gives regulators faster tools to act (for example, partial suspensions and flexible licence conditions), which could let authorities respond more quickly to suspected diversion — but it also raises questions about how those powers will be used and how businesses will be notified in non‑urgent cases.
• The government’s benefits are described qualitatively (reduced diversion and greater border control). The proposal also includes a public comment period before it could become final.